您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 骨科药物->治疗骨质疏松药物
处方药:处方药
包装规格: 50毫克/片
计价单位:
  点击放大  
生产厂家中文参考译名:
日本小野制药公司
生产厂家英文名:
Ono Pharmaceutical Co., Ltd
该药品相关信息网址1:
http://www.astellas.com/en/corporate/news/detail/approval-for-the-osteoprosis-t.html
该药品相关信息网址2:
http://www.astellas.com/en/corporate/news/
原产地英文商品名:
Bonoteo(ボノテオ) 50mg/tab
原产地英文药品名:
Minodronic acid hydrate
中文参考商品译名:
Bonoteo(ボノテオ) 50毫克/片
中文参考药品译名:
米诺膦酸
原产地国家批准上市年份:
2009/04/01
英文适应病症1:
Osteoporosis
临床试验期:
完成
中文适应病症参考翻译1:
骨质疏松症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2009112119503526.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

        Astellas和小野公司的口服二膦酸盐Bonoteo/Recalbon(minodronate)已在日本获批准用于治疗骨质疏松。对于每日服用一次的该药来说,此次批准在全球尚属首次。当地的Ⅲ期临床试验显示,与安慰剂相比,该药在脊柱骨折发生率方面有显著获益。同时公司还强调了1mg本品在肠胃副作用方面有很大的减少和高度有效。

Osteoporosis is a systemic bone disease characterized by decreased bone strength leading to an increased risk of bone fractures. It is estimated that over 10 million people, including potential patients, are suffering from the condition in Japan but that the number of patients continues to increase as aging population grows. Elderly osteoporosis patients in particular are liable to vertebral or femoral neck fracture keeping some of them in bed, and therefore measures to tackle the disease by not only therapeutic but social means have been an important issue.
Minodronic acid hydrate is an orally taken bisphosphonate that was first discovered in Japan and exhibits extremely potent inhibition of bone resorption* in the class. It is the first drug that demonstrated significant effect in prevention of bone fractures superior to placebo in Japanese osteoporosis patients in Phase III double blind comparative study.
It is expected that the drug, once launched, can contribute to the improvement of the patients' quality of life by offering an additional therapeutic option for the treatment of osteoporosis.
The drug will be available under the brand name of RECALBON® Tablets 1mg by Ono and Bonoteo® Tablets 1mg by Astellas respectively.
Bone resorption: The process by which osteoclasts break down old bone losing elasticity and hardness.
Dosage and administration:
Normally in adults, 1 mg of minodronic acid hydrate is taken orally together with enough amount of water (180 mL) (or lukewarm water) once a day at the time of awakening. The drug must be taken without lying down at least for 30 minutes before the first food, beverage (other than plain water), and other oral medication.
Distinctive features:
1. Minodronic acid hydrate is a bisphosphonate that was first discovered in Japan.
2. It is also the first bisphosphonate that demonstrated significant effect in prevention of bone fractures superior to placebo in Japanese osteoporosis patients.
3. It shows an excellent effect in increment of bone mineral density (BMD).
4. It also exhibits potent reduction of a bone resorption marker from the beginning of the treatment with the drug.
5. It exhibits extremely potent inhibition of bone resorption (in vitro and in rats).
6. The drug is in an easy-to-administrated small film coated tablet (6.6 mm in diameter, 3.0 mm thick.)
7. Incidence of adverse reactions (side effects) was observed in 18.6% (206 out of 1,108 patients) including abnormal laboratory test values, and those include stomach and abdominal discomfort in 35 patients (3.2%), abdominal pain in 27 patients (2.4%), decrease in blood calcium level in 22 patients (2.0%), and gastritis in 15 patients (1.4%). Disorders in upper gastrointestinal tract such as duodenal ulcer and gastric ulcer were reported as clinically significant adverse reactions.
Packaging:
RECALBON® Tablets 1mg: 100 tablets (blister packaging and bottle)
Bonoteo® Tablets 1mg: 100 tablets (blister packaging) and 500 tablets (bottle)
Source: Ono Pharmaceutical Co., Ltd

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2009112119503526.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2011-12-23
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com